- Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease | Biogen http://investors.biogen.com/news-releases/news-release-details/biogen-and-eisai-discontinue-phase-3-engage-and-emerge-trials 4 comments science
Linking pages
- FDA approves first drug intended to slow cognitive decline caused by Alzheimer’s disease - The Washington Post https://www.washingtonpost.com/health/2021/06/07/fda-approves-alzheimers-drug-aducanumab/ 16 comments
- Medicare proposes covering expensive drug for early-stage Alzheimer’s, but with restrictions that will sharply limit use - The Washington Post https://www.washingtonpost.com/health/2022/01/11/alzheimers-drug-aduhelm-medicare-coverage 9 comments
- Alzheimer's, Inc.: When a Hypothesis Becomes Too Big to Fail - Scientific American https://www.scientificamerican.com/article/alzheimers-inc-when-a-hypothesis-becomes-too-big-to-fail/ 2 comments
- Alzheimer’s drug aducanumab sparks emotional battle as FDA nears deadline on whether to approve - The Washington Post https://www.washingtonpost.com/health/2021/05/31/new-alzheimers-drug/ 1 comment
- For people with Down syndrome, a longer life, but under a cloud - The Washington Post https://www.washingtonpost.com/health/2022/04/07/down-syndrome-alzheimers-disease-aduhelm/ 1 comment
- New Alzheimer’s drug aducanumab: what we know so far – and why more research is still needed https://theconversation.com/new-alzheimers-drug-aducanumab-what-we-know-so-far-and-why-more-research-is-still-needed-162452 0 comments
Related searches:
Search whole site: site:investors.biogen.com
Search title: Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease | Biogen
See how to search.